<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medalphabet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский алфавит</journal-title><trans-title-group xml:lang="en"><trans-title>Medical alphabet</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-5631</issn><issn pub-type="epub">2949-2807</issn><publisher><publisher-name>ООО «Альфмед»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.33667/2078-5631-2025-9-23-27</article-id><article-id custom-type="elpub" pub-id-type="custom">medalphabet-4381</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Частота и факторы риска низкой минеральной плотности костной ткани у пациентов с системной склеродермией</article-title><trans-title-group xml:lang="en"><trans-title>The frequency and risk factors of low bone mineral density in patients with systemic sclerosis</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8155-6101</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Сорокина</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Sorokina</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сорокина Арина Олеговна - младший научный сотрудник лаборатории остеопороза.</p><p>Москва</p></bio><bio xml:lang="en"><p>Arina O. Sorokina - MD, junior researcher at Osteoporosis Dept.</p><p>Moscow</p></bio><email xlink:type="simple">ari1903@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2809-0197</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Добровольская</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Dobrovolskaya</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Добровольская Ольга Валерьевна - к.м.н., научный сотрудник лаборатории остеопороза.</p><p>Москва</p></bio><bio xml:lang="en"><p>Olga V. Dobrovolskaya - PhD Med, researcher at Osteoporosis Dept.</p><p>Moscow</p></bio><email xlink:type="simple">olgavdobr@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4739-4302</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Торопцова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Toroptsova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Торопцова Наталья Владимировна - д.м.н., зав. лабораторией остеопороза.</p><p>Москва</p></bio><bio xml:lang="en"><p>Natalia V. Toroptsova - DM Sci (habil.), head of Osteoporosis Dept.</p><p>Moscow</p></bio><email xlink:type="simple">torop@irramn.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>06</day><month>06</month><year>2025</year></pub-date><volume>0</volume><issue>9</issue><issue-title>Ревматология в общей врачебной практике (1)</issue-title><fpage>23</fpage><lpage>27</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Сорокина А.О., Добровольская О.В., Торопцова Н.В., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Сорокина А.О., Добровольская О.В., Торопцова Н.В.</copyright-holder><copyright-holder xml:lang="en">Sorokina A.O., Dobrovolskaya O.V., Toroptsova N.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-alphabet.com/jour/article/view/4381">https://www.med-alphabet.com/jour/article/view/4381</self-uri><abstract><p>Цель исследования – изучить частоту встречаемости низкой минеральной плотности кости (МПК) у пациентов с системной склеродермией (ССД) и определить факторы, влияющие на состояние МПК.</p><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование были включены 210 пациентов с ССД (медиана возраста 52,0 [41,3; 62,1] года): 165 (78,6 %) женщин и 45 (21,4 %) мужчин. МПК оценивали с помощью двухэнергетической рентгеновской абсорбциометрии (DXA). У женщин в постменопаузе и мужчин старше 50 лет ОП диагностировали при значении T-критерия в любой области измерения &lt; –2,5 СО, а у фертильных женщин и мужчин моложе 50 лет сниженная МПК выявлялась при значении Z-критерия &lt; –2,0 СО. Для выявления факторов, связанных с ОП/ сниженной МПК, была проведена логистическая регрессия.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. ОП/низкая МПК были выявлены у 63 (30,0 %) человек. Многофакторный логистический анализ показал взаимосвязь между ОП/низкой МПК и возрастом (отношение шансов (ОШ) 1,03; [95 % доверительный интервал (ДИ) 1,01; 1,07]; р&lt;0,05), индексом массы тела (ИМТ) ≤24 кг/м2 (ОШ 3,81; [95 % ДИ 1,76; 8,07]; р&lt;0,001), акроостеолизом дистальных фаланг кистей (ОШ 4,56; [95 % ДИ 1,29; 16,17]; р&lt;0,05), длительностью приема глюкокортикоидов (ГК) (ОШ 1,07; [95 % ДИ 1,01; 1,14]; р&lt;0,05), позитивностью по антителам (АТ) к топоизомеразе I (АТ к Scl 70+) (ОШ 2,07; [95 % ДИ 1,06; 4,16]; р&lt;0,05).</p></sec><sec><title>Выводы</title><p>Выводы. ОП/низкая МПК диагностированы у 30,0 % обследованных пациентов с ССД. Возраст, ИМТ ≤24 кг/м2, акроостеолиз дистальных фаланг кистей, длительность приема ГК и позитивность по АТ к Scl 70+ являлись факторами, негативно влияющими на состояние МПК.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Objective</title><p>Objective. To study the frequency of low bone mineral density (BMD) and BMD-related factors in patients with systemic sclerosis (SSc).</p></sec><sec><title>Material and Methods</title><p>Material and Methods. 210 patients with SSc (median age 52,0 [41,3; 62,1] years) were included: 165 (78,6 %) women and 45 (21,4 %) men. BMD was measured by DXA. In postmenopausal women and men ≥ 50 years OP was diagnosed with T-score at any region &lt; –2.5 SD, in fertile women and men under 50 years of age low BMD was detected with – Z-score &lt;-2.0 SD. To identify the factors associated with low BMD, a logistic regression analysis was performed.</p></sec><sec><title>Results</title><p>Results. Low BMD was detected in 63 (30,0 %) persons. Multivariate analysis showed association between low BMD and age (OR 1,03; [95 % CI 1,01; 1,07]; р&lt;0,05), body mass index (BMI) ≤24 kg/m2 (OR 3,81; [95 % CI 1,76; 8,07]; p &lt; 0.001), acroosteolysis (AO) of distal phalanges (OR 4,56; [95 % CI 1,29; 16,17]; р&lt;0,05), duration of glucocorticoids (GСs) taking (OR1,07; [95% CI 1,01; 1,14]; р&lt;0,05) and anti-topoisomerase I positivity (OR 2,07; [95% CI 1,06; 4,16]; р&lt;0,05).</p></sec><sec><title>Conclusion</title><p>Conclusion. Low BMD was detected in 63 (30,0 %) persons. Age, BMI ≤24 kg/m2, AO of distal phalanges, duration of GСs taking and antitopoisomerase I positivity increased the risk of OP/low BMD in patients with SSc.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>остеопения</kwd><kwd>остеопороз</kwd><kwd>системная склеродермия</kwd><kwd>минеральная плотность кости</kwd><kwd>факторы риска</kwd></kwd-group><kwd-group xml:lang="en"><kwd>osteopenia</kwd><kwd>osteoporosis</kwd><kwd>systemic sclerosis</kwd><kwd>bone mineral density</kwd><kwd>risk factors</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проводилось в рамках научной темы № РК 125020501433–4 и было одобрено локальным этическим комитетом ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой».</funding-statement><funding-statement xml:lang="en">The study was conducted within the framework of scientific topic No. РК 125020501433–4 and was approved by the local ethics committee of the V.A. Nasonova Research Institute of Rheumatology.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">NIH Consensus Development Conference on Osteoporosis: Prevention, Diagnosis and Therapy. JAMA. 2000; 287: 785–95.</mixed-citation><mixed-citation xml:lang="en">NIH Consensus Development Conference on Osteoporosis: Prevention, Diagnosis and Therapy. JAMA. 2000; 287: 785–95.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014 Oct; 25 (10): 2359–81. DOI: 10.1007/s00198-014-2794-2. Epub 2014 Aug 15. Erratum in: Osteoporos Int. 2015 Jul; 26 (7): 2045–7. DOI: 10.1007/s00198-015-3037-x. PMID: 25182228; PMCID: PMC 4176573.</mixed-citation><mixed-citation xml:lang="en">Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Osteoporos Int. 2014 Oct; 25 (10): 2359–81. DOI: 10.1007/s00198-014-2794-2. Epub 2014 Aug 15. Erratum in: Osteoporos Int. 2015 Jul; 26 (7): 2045–7. DOI: 10.1007/s00198-015-3037-x. PMID: 25182228; PMCID: PMC 4176573.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009 May 7; 360 (19): 1989–2003. DOI: 10.1056/NEJMra0806188. PMID: 19420368.</mixed-citation><mixed-citation xml:lang="en">Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009 May 7; 360 (19): 1989–2003. DOI: 10.1056/NEJMra0806188. PMID: 19420368.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Binder E. F. (2008 Jun), Kiel D. P. (2008) Genetics of the musculoskeletal system: a pleiotropic approach. J Bone Miner Res. 23 (6): 788–802. https://doi.org/10.1359/jbmr.080218</mixed-citation><mixed-citation xml:lang="en">Binder E. F. (2008 Jun), Kiel D. P. (2008) Genetics of the musculoskeletal system: a pleiotropic approach. J Bone Miner Res. 23 (6): 788–802. https://doi.org/10.1359/jbmr.080218</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Omair MA, Pagnoux C, McDonald-Blumer H, Johnson SR. Low bone density in systemic sclerosis. A systematic review. J Rheumatol. 2013 Nov; 40 (11): 1881–90. DOI: 10.3899/jrheum.130032. Epub 2013 Sep 15. PMID: 24037552.</mixed-citation><mixed-citation xml:lang="en">Omair MA, Pagnoux C, McDonald-Blumer H, Johnson SR. Low bone density in systemic sclerosis. A systematic review. J Rheumatol. 2013 Nov; 40 (11): 1881–90. DOI: 10.3899/jrheum.130032. Epub 2013 Sep 15. PMID: 24037552.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Avouac J., Koumakis E., Toth E., Meunier M., Maury E., Kahan A., Cormier C., Allanore Y., Arthritis Care Res (Hoboken), Increased Risk of Osteoporosis and Fracture in Women with Systemic Sclerosis: A Comparative Study with Rheumatoid Arthritis Ю, Arthritis Care &amp; Research. 2012 Dec; 64 (12): 1871–1878. DOI: 10.1002/acr.21761</mixed-citation><mixed-citation xml:lang="en">Avouac J., Koumakis E., Toth E., Meunier M., Maury E., Kahan A., Cormier C., Allanore Y., Arthritis Care Res (Hoboken), Increased Risk of Osteoporosis and Fracture in Women with Systemic Sclerosis: A Comparative Study with Rheumatoid Arthritis Ю, Arthritis Care &amp; Research. 2012 Dec; 64 (12): 1871–1878. DOI: 10.1002/acr.21761</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Marighela T. F., Genaro Pde S., Pinheiro M. M., Szejnfeld V. L., Kayser C. Risk factors for body composition abnormalities in systemic sclerosis. Clin Rheumatol. 2013; 32 (7): 1037–1044. DOI: 10.1007/s10067-013-2235-1</mixed-citation><mixed-citation xml:lang="en">Marighela T. F., Genaro Pde S., Pinheiro M. M., Szejnfeld V. L., Kayser C. Risk factors for body composition abnormalities in systemic sclerosis. Clin Rheumatol. 2013; 32 (7): 1037–1044. DOI: 10.1007/s10067-013-2235-1</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Corrado A., Colia R., Mele A. et al. Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis [published correction appears in PLoS One. 2015; 10 (11): e0142748]. PLoS One. 2015; 10 (9): e0137912. Published 2015 Sep 16. DOI: 10.1371/journal.pone.0137912</mixed-citation><mixed-citation xml:lang="en">Corrado A., Colia R., Mele A. et al. Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis [published correction appears in PLoS One. 2015; 10 (11): e0142748]. PLoS One. 2015; 10 (9): e0137912. Published 2015 Sep 16. DOI: 10.1371/journal.pone.0137912</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Marot M., Valéry A., Esteve E. et al. Prevalence and predictive factors of osteoporosis in systemic sclerosis patients: a case-control study. Oncotarget. 2015; 6 (17): 14865–14873. DOI: 10.18632/oncotarget.3806</mixed-citation><mixed-citation xml:lang="en">Marot M., Valéry A., Esteve E. et al. Prevalence and predictive factors of osteoporosis in systemic sclerosis patients: a case-control study. Oncotarget. 2015; 6 (17): 14865–14873. DOI: 10.18632/oncotarget.3806</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Caimmi C., Caramaschi P., Barausse G. et al. Bone Metabolism in a Large Cohort of Patients with Systemic Sclerosis. Calcif Tissue Int. 2016; 99 (1): 23–29. DOI: 10.1007/s00223-016-0119-5</mixed-citation><mixed-citation xml:lang="en">Caimmi C., Caramaschi P., Barausse G. et al. Bone Metabolism in a Large Cohort of Patients with Systemic Sclerosis. Calcif Tissue Int. 2016; 99 (1): 23–29. DOI: 10.1007/s00223-016-0119-5</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Thietart S., Louati K., Gatfosse M. et al. Overview of osteo-articular involvement in systemic sclerosis: Specific risk factors, clinico-sonographic evaluation, and comparison with healthy women from the French OFELY cohort. Best Pract Res Clin Rheumatol. 2018; 32 (4): 591–604. DOI: 10.1016/j.berh.2019.01.008</mixed-citation><mixed-citation xml:lang="en">Thietart S., Louati K., Gatfosse M. et al. Overview of osteo-articular involvement in systemic sclerosis: Specific risk factors, clinico-sonographic evaluation, and comparison with healthy women from the French OFELY cohort. Best Pract Res Clin Rheumatol. 2018; 32 (4): 591–604. DOI: 10.1016/j.berh.2019.01.008</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Paolino S., Gotelli E., Goegan F. et al. Body composition and bone status in relation to microvascular damage in systemic sclerosis patients. J Endocrinol Invest. 2021; 44 (2): 255–264. DOI: 10.1007/s40618-020-01234-4</mixed-citation><mixed-citation xml:lang="en">Paolino S., Gotelli E., Goegan F. et al. Body composition and bone status in relation to microvascular damage in systemic sclerosis patients. J Endocrinol Invest. 2021; 44 (2): 255–264. DOI: 10.1007/s40618-020-01234-4</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Chuealee W., Foocharoen C., Mahakkanukrauh A., Suwannaroj S., Pongchaiyakul C., Nanagara R. Prevalence and predictive factors of osteoporosis in Thai systemic sclerosis. Sci Rep. 2021; 11 (1): 9424. Published 2021 May 3. DOI: 10.1038/s41598-021-88792-6</mixed-citation><mixed-citation xml:lang="en">Chuealee W., Foocharoen C., Mahakkanukrauh A., Suwannaroj S., Pongchaiyakul C., Nanagara R. Prevalence and predictive factors of osteoporosis in Thai systemic sclerosis. Sci Rep. 2021; 11 (1): 9424. Published 2021 May 3. DOI: 10.1038/s41598-021-88792-6</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Cantero-Nieto L., Álvarez-Cienfuegos A., García-Gómez J.A., Ríos-Fernández R., Robledo G., Ortego-Centeno N. Association between FGF-23 levels and risk of fracture in women with systemic sclerosis. J Clin Densitom. 2021; 24 (3): 362–368. DOI: 10.1016/j.jocd.2020.05.010</mixed-citation><mixed-citation xml:lang="en">Cantero-Nieto L., Álvarez-Cienfuegos A., García-Gómez J.A., Ríos-Fernández R., Robledo G., Ortego-Centeno N. Association between FGF-23 levels and risk of fracture in women with systemic sclerosis. J Clin Densitom. 2021; 24 (3): 362–368. DOI: 10.1016/j.jocd.2020.05.010</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Bimal G., Sahhar J., Savanur M., Ngian G. S. Screening rates and prevalence of osteoporosis in a real-world, Australian systemic sclerosis cohort. Int J Rheum Dis. 2022; 25 (2): 175–181. DOI: 10.1111/1756-185X.14254</mixed-citation><mixed-citation xml:lang="en">Bimal G., Sahhar J., Savanur M., Ngian G. S. Screening rates and prevalence of osteoporosis in a real-world, Australian systemic sclerosis cohort. Int J Rheum Dis. 2022; 25 (2): 175–181. DOI: 10.1111/1756-185X.14254</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Иванова Ю. Ю., Бугрова О. В., Беляева О. Н., Полищук И. С., Сайфутдинов Р. И., Щавелева Л. А. Некоторые факторы риска остеопороза у пациентов с системной склеродермией. Оренбургский медицинский вестник. Т. Х. 2022; 3 (39): 29–32.</mixed-citation><mixed-citation xml:lang="en">Ivanova Yu. Yu., Bugrova O. V., Belyaeva O. N., Polishchuk I. S., Sayfutdinov R. I., Shaveleva L. A. Some risk factors for osteoporosis in patients with systemic sclerosis. Orenburg medical herald. Book X. 2022; 3 (39): 29–32.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Tu X., Li C., Zhuang M., Liu L., Xu C., Wang J. High prevalence and risk factors for osteoporosis in 1839 patients with systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol. 2023; 42 (4): 1087–1099. DOI: 10.1007/s10067-022-06460-0</mixed-citation><mixed-citation xml:lang="en">Tu X., Li C., Zhuang M., Liu L., Xu C., Wang J. High prevalence and risk factors for osteoporosis in 1839 patients with systemic sclerosis: a systematic review and meta-analysis. Clin Rheumatol. 2023; 42 (4): 1087–1099. DOI: 10.1007/s10067-022-06460-0</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mok C. C., Chan P. T., Chan K. L., Ma K. M. Prevalence and risk factors of low bone mineral density in Chinese patients with systemic sclerosis: a case-control study. Rheumatology (Oxford). 2013; 52 (2): 296–303. DOI: 10.1093/rheumatology/kes240</mixed-citation><mixed-citation xml:lang="en">Mok C. C., Chan P. T., Chan K. L., Ma K. M. Prevalence and risk factors of low bone mineral density in Chinese patients with systemic sclerosis: a case-control study. Rheumatology (Oxford). 2013; 52 (2): 296–303. DOI: 10.1093/rheumatology/kes240</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Midol C., Wiebe E., Siegert E. et al. Risk of Osteoporosis in Patients with Systemic Sclerosis: A Cross-Sectional Analysis of Two European Prospective Cohorts [abstract]. Arthritis Rheumatol. 2021; 73 (suppl. 10).</mixed-citation><mixed-citation xml:lang="en">Midol C., Wiebe E., Siegert E. et al. Risk of Osteoporosis in Patients with Systemic Sclerosis: A Cross-Sectional Analysis of Two European Prospective Cohorts [abstract]. Arthritis Rheumatol. 2021; 73 (suppl. 10).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ibn Yacoub Y., Amine B., Laatiris A., Wafki F., Znat F., Hajjaj-Hassouni N. Bone density in Moroccan women with systemic scleroderma and its relationships with disease-related parameters and vitamin D status. Rheumatol Int. 2012; 32 (10): 3143–3148. DOI: 10.1007/s00296-011-2150-1</mixed-citation><mixed-citation xml:lang="en">Ibn Yacoub Y., Amine B., Laatiris A., Wafki F., Znat F., Hajjaj-Hassouni N. Bone density in Moroccan women with systemic scleroderma and its relationships with disease-related parameters and vitamin D status. Rheumatol Int. 2012; 32 (10): 3143–3148. DOI: 10.1007/s00296-011-2150-1</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Loucks J, Pope JE. Osteoporosis in scleroderma. Semin Arthritis Rheum. 2005 Feb; 34 (4): 678–82. DOI: 10.1016/j.semarthrit.2004.08.006. PMID: 15692961.</mixed-citation><mixed-citation xml:lang="en">Loucks J, Pope JE. Osteoporosis in scleroderma. Semin Arthritis Rheum. 2005 Feb; 34 (4): 678–82. DOI: 10.1016/j.semarthrit.2004.08.006. PMID: 15692961.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Taylan A., Birlik M., Kenar G. et al. Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/ RANKL/TRAIL and Wnt inhibitors. Mod Rheumatol. 2019; 29 (4): 619–624. DOI: 10.1080/14397595.2018.1500736</mixed-citation><mixed-citation xml:lang="en">Taylan A., Birlik M., Kenar G. et al. Osteoprotegrin interacts with biomarkers and cytokines that have roles in osteoporosis, skin fibrosis, and vasculopathy in systemic sclerosis: A potential multifaceted relationship between OPG/ RANKL/TRAIL and Wnt inhibitors. Mod Rheumatol. 2019; 29 (4): 619–624. DOI: 10.1080/14397595.2018.1500736</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Midol C., Wiebe E., Siegert E. et al. Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis. Rheumatology (Oxford). Published online March 7, 2024. DOI: 10.1093/rheumatology/keae142</mixed-citation><mixed-citation xml:lang="en">Midol C., Wiebe E., Siegert E. et al. Osteoporosis is associated with anti-topoisomerase I positivity and glucocorticoids use in patients with systemic sclerosis. Rheumatology (Oxford). Published online March 7, 2024. DOI: 10.1093/rheumatology/keae142</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Lescoat A., Leroy M., Coiffier G. et al. Bone mineral density and trabecular bone score assessment in systemic sclerosis: A cross-sectional study. Joint Bone Spine. 2021; 88 (5): 105214. DOI: 10.1016/j.jbspin.2021.105214</mixed-citation><mixed-citation xml:lang="en">Lescoat A., Leroy M., Coiffier G. et al. Bone mineral density and trabecular bone score assessment in systemic sclerosis: A cross-sectional study. Joint Bone Spine. 2021; 88 (5): 105214. DOI: 10.1016/j.jbspin.2021.105214</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Midol C., Wiebe E., Siegert E. et al. Risk of Osteoporosis in Patients with Systemic Sclerosis: A Cross-Sectional Analysis of Two European Prospective Cohorts [abstract]. Arthritis Rheumatol. 2021; 73 (suppl. 10).</mixed-citation><mixed-citation xml:lang="en">Midol C., Wiebe E., Siegert E. et al. Risk of Osteoporosis in Patients with Systemic Sclerosis: A Cross-Sectional Analysis of Two European Prospective Cohorts [abstract]. Arthritis Rheumatol. 2021; 73 (suppl. 10).</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Jamal SA, Swan VJ, Brown JP. et al. Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study [retracted in: Am J Kidney Dis. 2016 Aug;68(2):333]. Am J Kidney Dis. 2010; 55 (2): 291–299. DOI: 10.1053/j.ajkd.2009.10.049</mixed-citation><mixed-citation xml:lang="en">Jamal SA, Swan VJ, Brown JP. et al. Kidney function and rate of bone loss at the hip and spine: the Canadian Multicentre Osteoporosis Study [retracted in: Am J Kidney Dis. 2016 Aug;68(2):333]. Am J Kidney Dis. 2010; 55 (2): 291–299. DOI: 10.1053/j.ajkd.2009.10.049</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Klawansky S, Komaroff E, Cavanaugh PF Jr. et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003; 14 (7): 570–576. DOI: 10.1007/s00198-003-1435-y</mixed-citation><mixed-citation xml:lang="en">Klawansky S, Komaroff E, Cavanaugh PF Jr. et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int. 2003; 14 (7): 570–576. DOI: 10.1007/s00198-003-1435-y</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
